|
Seeding
SEZs
With the introduction of the Special Economic Zone (SEZ) Act
in India in February, the SEZs are set for vigorous growth.
There is renewed interest amongst pharma and biotech companies
as they prepare to tap this opportunity, learns Sapna Dogra
Sun
Pharma posts impressive Q4 results
Sun Pharmaceutical Indus-tries reported strong Q4 performance
for FY05-06.
Zydus
Cadila receives approval for warfarin tablets
Zydus Cadila has received approval from the USFDA to market
warfarin tablets in different strengths of one milligram,
two milligram, 2.5 milligram, three milligram, four milligram,
five milligram, six milligram, 7.5 milligram and ten milligram.
Glenmark
and Paul Capital sign royalty deal
Glenmark Pharmaceuticals announced a unique royalty deal with
Paul Capital Partners' Royalty. Under the terms of the arrangement,
Paul Royalty will invest up to $27 million to finance the
development of 16 dermatological products by Glenmark for
the US market.
Zydus-Cadila
gets a marketing makeover
The Rs 1,200 crore Zydus Cadila Group is in the process of
consolidating its presence in the market. The company is implementing
project Phoenix, aimed at creating newer market for its 'mature'
brands and devising newer usage for its pillar brands in the
Indian market.
Indegene
and GSK win Global Pyramid Award
Indegene, medical and scientific marketing services provider
has partnered with GlaxoSmithKline Consumer Healthcare (GSKCH)
India, to win the Global Pyramid Award for excellence in medical
marketing in the category, 'Best use of science'.
Anvisa
approves Alkem's Manufacturing Unit
Alkem Laboratories' sterile cephalosporin and beta lactam
manufacturing unit at Daman has received approval from Agencia
Nacional de Vigilancia Sanitaria (ANVISA).
Lupin
gets USFDA approval for Cefdinir suspension
Lupin announced that USFDA has approved the company's ANDA
for Cefdinir Suspension 125mg or 5mL.
'There
is a super normal growth in NDDS'
As one of the forerunners in the NDDS segment, Ethypharm India,
the 100 percent subsidiary of French MNC pharma major, Ethypharm
SA, recently signed an out-licensing and supply contract with
Ranbaxy for its product, Tramadol Flashtab. Ajey Kumar, CEO,
Ethypharm India talks at length to Sonal Shukla about the
NDDS market and the future plans of the company.
Products
|
